Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer

(University of Texas M. D. Anderson Cancer Center) Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news